SCHEDULE: Goldman Sachs Discloses 7.5% Stake in 4D Molecular
Ownership Disclosure
Goldman Sachs Group and its affiliate Goldman Sachs & Co. LLC have reported a 7.5% beneficial ownership in 4D Molecular Therapeutics, Inc. common stock.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly reported beneficial ownership of 4,286,077.48 shares of 4D MOLECULAR THERAPEUTICS, INC. Common Stock.
- This aggregate amount represents 7.5% of the issuer's class of securities.
- The reporting entities hold shared voting power over 4,286,060.48 shares and shared dispositive power over 4,286,077.48 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a previous disclosure of ownership.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, typical for an institutional ownership disclosure. It provides transparency regarding a significant stake but offers no new operational or financial insights into the issuer.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures by institutional investors who acquire more than 5% of a company's stock, indicating passive investment intent. This filing confirms Goldman Sachs' continued significant, but passive, stake in 4D Molecular Therapeutics, a biotechnology company, which is common for large financial institutions managing diverse portfolios.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact for SEC filings | Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves, Veronica Mupazviriwo, Elizabeth Novak and Sam Prashanth (for The Goldman Sachs Group, Inc.) | Sadhiya Raffique, Santosh Vinayagamoorthy, D Guru Prasad, Tobi Amusan, Akash Keshari, Papa Lette, Andrzej Szyszka, Rahail Patel, Taiki Misu, Regina Chan, Mariana Audeves Martinez, Asheesh Bajaj, Abhilasha Bareja, Veronica Mupazviriwo, Sam Prashanth, Ameen Soetan, Abhishek Vishwanathan, Elizabeth Novak and Matthew Pomfret (for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC) | 2025-07-16 | Superseding of previous Power of Attorney, updating the list of authorized individuals. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC issued new Powers of Attorney, superseding previous ones, to authorize a revised list of individuals to execute SEC filings on their behalf. | 2025-07-16 | Streamlines the process for SEC filings by updating the authorized signatories, ensuring compliance and operational efficiency for the reporting entities. |
Stakeholder Impact
- Shareholders of 4D Molecular Therapeutics, Inc. gain transparency regarding a significant institutional investor's stake, confirming Goldman Sachs' continued passive investment in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. was superseded. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC was superseded. |
| 2025-07-16 | New Power of Attorney granted by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, effective until July 16, 2026. |
| 2025-12-31 | Date of event which requires the filing of this statement (reporting period end date for ownership). |
| 2026-01-06 | Date of filing and signature by attorney-in-fact Sam Prashanth. |
| 2026-07-16 | Expiration date of the current Power of Attorney. |
Keywords
Goldman Sachs, 4D Molecular Therapeutics, Institutional Ownership, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.